Search Results - "González‐Barrallo, Inés"

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients by Pineda, Begoña, Diaz-Lagares, Angel, Pérez-Fidalgo, José Alejandro, Burgués, Octavio, González-Barrallo, Inés, Crujeiras, Ana B, Sandoval, Juan, Esteller, Manel, Lluch, Ana, Eroles, Pilar

“…Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To…”
Get full text

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study by Gambardella, Valentina, Lombardi, Pasquale, Carbonell-Asins, Juan Antonio, Tarazona, Noelia, Cejalvo, Juan Miguel, González-Barrallo, Inés, Martín-Arana, Jorge, Tébar-Martínez, Roberto, Viala, Alba, Bruixola, Gema, Hernando, Cristina, Blasco, Inma, Papaccio, Federica, Martínez-Ciarpaglini, Carolina, Alfaro-Cervelló, Clara, Seda-García, Enrique, Blesa, Sebastián, Chirivella, Isabel, Castillo, Josefa, Montón-Bueno, José Vicente, Roselló, Susana, Huerta, Marisol, Pérez-Fidalgo, Alejandro, Martín-Martorell, Paloma, Insa-Mollá, Amelia, Fleitas, Tania, Rentero-Garrido, Pilar, Zúñiga-Trejos, Sheila, Cervantes, Andrés, Roda, Desamparados

“…Introduction Molecular-matched therapies have revolutionized cancer treatment. We evaluated the improvement in clinical outcomes of applying an in-house…”
Get full text

Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL) by González-Barrallo, Inés, Castellón Rubio, Victoria Eugenia, Medina, Javier, España, Sofia, Mujika, Karmele, Majem, Margarita, Aguado, Carlos, Cabrera Suárez, Miguel Ángel, Palacio, Isabel, Osterloh, Lisa, Martínez-Fernández, Alejandro, García-Castaño, Almudena

“…Efficacy and safety of dabrafenib and trametinib in metastatic melanoma have been demonstrated in two-phase III and one-phase I/II clinical trials. However,…”
Get full text

Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first‐line anti‐programmed death‐1 monotherapy: A real‐world multicentre observational cohort study by Ochenduszko, Sebastian, García Sanchez, Javier, Fita, María José Juan, González‐Barrallo, Inés, Herrero Colomina, Julio, Mujika, Karmele, Beveridge, Roberto Diaz, Martínez, Silverio Ros, Lafuente, Blanca Sánchez, Tomas, Alberto Cunquero, Jaime, Alfonso Berrocal, Cerezuela Fuentes, Pablo, Fra, Pablo Luna, Peeters, Alicia Gervás, Meana García, José Andrés, García, María Asunción Algarra, Altozano, Javier Perez, Cancela, Maria, Puchades, Almudena Mateu, Roca, Francisco Ferrando, Maiques, Inmaculada Maestu

“…Anti‐programmed death‐1 (anti‐PD1) treatment has significantly improved outcomes of advanced melanoma with a considerable percentage of patients achieving…”
Get full text

Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL) by González-Barrallo, Inés, Castellón Rubio, Victoria Eugenia, Medina, Javier, España, Sofia, Mujika, Karmele, Majem, Margarita, Aguado, Carlos, Cabrera Suárez, Miguel Ángel, Palacio, Isabel, Osterloh, Lisa, Martínez-Fernández, Alejandro, García-Castaño, Almudena

“…Efficacy and safety of dabrafenib and trametinib in metastatic melanoma have been demonstrated in two-phase III and one-phase I/II clinical trials. However,…”
Get full text

Melanoma fusocelular parotídeo con primario desconocido by Silva Díaz, Esmeralda, Martín Hernández, José María, González Barrallo, Inés, Terrádez Más, Liria

Get full text

Real-world study on characteristics of advanced melanoma patients with sustained complete response (CR) after elective 1 st line anti-programmed death-1 (anti-PD1) monotherapy discontinuation by Ochenduszko, Sebastian, García, Javier, Juan-Fita, María Jose, Gonzalez-Barrallo, Ines, Herrero Colomina, Julio, Diaz Beveridge, Robert, Ros Martinez, Silverio, Sanchez Lafuente, Blanca, Cunquero Tomas, Alberto Jacobo, Berrocal, Alfonso, Cerezuela-Fuentes, Pablo, Luna Fra, Pablo, Gervás Peeters, Alicia, Sanchez Gonzalez, José Luis, Meana Garcia, Andres, Algarra Garcia, Mariasun, Palomares García, Eugenio, Perez Altozano, Javier, Tallón Guerola, Mónica, Maestu, Inmaculada

“…e21529 Background: Previous reports proved the feasibility of immunotherapy (IT) discontinuation in advanced melanoma (MEL) patients (pts) in case of CR. We…”
Get full text

DNA methylation as an epigenetic signature predictive of response to neodjuvant treatment in TNBC patients by Pineda, Begona, Perez-Fidalgo, Jose Alejandro, Díaz-Lagares, Angel, Burgues, Octavio, Gonzalez-Barrallo, Ines, Crujeiras, Ana Belen, Sandoval, Juan, Esteller, Manel, Eroles, Pilar, Lluch, Ana

“…Abstract only…”
Get full text

SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry by Gonzalez-Cao, Maria, Puertolas, Teresa, Martinez-Vila, Clara, Carrera, Cristina, Maldonado Seral, Cayetana, Rodríguez-Jiménez, Pedro, Sequero, Silvia, Cerezuela-Fuentes, Pablo, Feltes Ochoa, Rosa, Muñoz, Eva, Antoñanzas Basa, Mónica, Martín-Liberal, Juan, Soria, Ainara, Francisco Rodriguez Moreno, Juan, Marquez-Rodas, Ivan, Lopez Criado, Pilar, Luis Manzano, José, Lopez-Castro, Rafael, Ayala de Miguel, Pablo, Villalobos, Laura, Martin Algarra, Salvador, Gonzalez-Barrallo, Ines, Boada, Aram, García Castaño, Almudena, Puig, Susana, Crespo, Guillermo, Luna Fra, Pablo, Aguayo Zamora, Cristina, Feito Rodríguez, Marta, Valles, Lara, Drozdowskyj, Ana, Gardeazabal, Jesús, Antonio Fernandez-Morales, Luis, Rodrigo, Alberto, Cruz, Raquel, Yelamos, Oriol, Rubio, Belen, Mujica, Karmele, Provencio, Mariano, Berrocal, Alfonso

“…Background The Spanish Melanoma Group (GEM) developed a national registry of patients with melanoma infected by SARS-CoV-2 (“GRAVID”). Methods The main…”
Get full text